Company: FENC
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001558370-25-005563
Chunk: 10

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 10
---
 the Board promptly following the applicable Shareholders’ meeting. Following receipt of resignation, the Governance and Nominating Committee will consider whether or not to accept the offer of resignation and make a recommendation to the Board. Within 90 days following the applicable Shareholders’ meeting, the Board shall publicly disclose in a news release their decision whether to accept the applicable director’s resignation or not, including the reasons for rejecting the resignation, if applicable. The Board shall accept the resignation absent exceptional circumstances. A director who tenders his or her resignation pursuant to this policy will not be permitted to participate in any meeting of the Board or the Governance and Nominating Committee at which the resignation is considered. A copy of the majority voting policy may be found on the Fennec website at www.fennecpharma.com.

The following table sets forth the name of each of our executive officers and directors, such person’s principal occupation or employment, all other positions with Fennec and any significant affiliate thereof now held by such person, if any, the year in which such person became a director of Fennec and such person’s age.

<div align='center'>Page7</div>

The Corporation has an Audit Committee, a Compensation Committee, and a Governance and Nominating Committee. The current members of such committees are noted below.

| ​                                                                          | ​ |   ​ | ​ | ​                                                                                                                                                                               | ​ | ​              | ​ |       ​ | ​ |          ​ |
| ​                                                                          | ​ |   ​ |   | ​                                                                                                                                                                               |   | ​              |   |       ​ |   | Options to |
| ​                                                                          | ​ |   ​ |   | Current Principal Occupation                                                                                                                                                    |   | ​              |   |  Common |   |    Acquire |
| Name and Province/State and                                                | ​ |   ​ |   | and Principal Occupation for                                                                                                                                                    | ​ | Director       |   |  Shares |   |     Common |
| Country of Residence, Position                                             | ​ | Age | ​ | Previous Five Years                                                                                                                                                             | ​ | Since          | ​ |    Held |   |     Shares |
| Jeff Hackman, Massachusetts, USA Chief Executive Officer, Director         | ​ |  63 | ​ | CEO and Director of Fennec Pharmaceuticals; Chairman and CEO of Comera Life Sciences; director and CEO of Legacy Comera                                                         | ​ | August 2024    | ​ |       — | ​ |    450,000 |
| Rostislav Raykov, New